427 related articles for article (PubMed ID: 22257681)
21. Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells.
Sasidharan Nair V; Elkord E
Immunol Cell Biol; 2018 Jan; 96(1):21-33. PubMed ID: 29359507
[TBL] [Abstract][Full Text] [Related]
22. Tuning cancer fate: the unremitting role of host immunity.
Calì B; Molon B; Viola A
Open Biol; 2017 Apr; 7(4):. PubMed ID: 28404796
[TBL] [Abstract][Full Text] [Related]
23. Signaling defects in anti-tumor T cells.
Frey AB; Monu N
Immunol Rev; 2008 Apr; 222():192-205. PubMed ID: 18364003
[TBL] [Abstract][Full Text] [Related]
24. Immunomodulating and Immunoresistance Properties of Cancer-Initiating Cells: Implications for the Clinical Success of Immunotherapy.
Maccalli C; Parmiani G; Ferrone S
Immunol Invest; 2017 Apr; 46(3):221-238. PubMed ID: 28287848
[TBL] [Abstract][Full Text] [Related]
25. MHC heterogeneity and response of metastases to immunotherapy.
Algarra I; Garrido F; Garcia-Lora AM
Cancer Metastasis Rev; 2021 Jun; 40(2):501-517. PubMed ID: 33860434
[TBL] [Abstract][Full Text] [Related]
26. NK cells and cancer immunosurveillance.
Waldhauer I; Steinle A
Oncogene; 2008 Oct; 27(45):5932-43. PubMed ID: 18836474
[TBL] [Abstract][Full Text] [Related]
27. The Tolerogenic Function of Regulatory T Cells in Pregnancy and Cancer.
Jørgensen N; Persson G; Hviid TVF
Front Immunol; 2019; 10():911. PubMed ID: 31134056
[TBL] [Abstract][Full Text] [Related]
28. Roles of regulatory T cells in cancer immunity.
Takeuchi Y; Nishikawa H
Int Immunol; 2016 Aug; 28(8):401-9. PubMed ID: 27160722
[TBL] [Abstract][Full Text] [Related]
29. Cellular and molecular mechanisms in cancer immune escape: a comprehensive review.
Bhatia A; Kumar Y
Expert Rev Clin Immunol; 2014 Jan; 10(1):41-62. PubMed ID: 24325346
[TBL] [Abstract][Full Text] [Related]
30. Regulatory B cell: New member of immunosuppressive cell club.
Ding T; Yan F; Cao S; Ren X
Hum Immunol; 2015 Sep; 76(9):615-21. PubMed ID: 26385479
[TBL] [Abstract][Full Text] [Related]
31. Regulatory T cells in immune surveillance and treatment of cancer.
Yamaguchi T; Sakaguchi S
Semin Cancer Biol; 2006 Apr; 16(2):115-23. PubMed ID: 16376102
[TBL] [Abstract][Full Text] [Related]
32. Tumors attenuating the mitochondrial activity in T cells escape from PD-1 blockade therapy.
Kumar A; Chamoto K; Chowdhury PS; Honjo T
Elife; 2020 Mar; 9():. PubMed ID: 32122466
[TBL] [Abstract][Full Text] [Related]
33. Mechanisms of immune evasion in breast cancer.
Bates JP; Derakhshandeh R; Jones L; Webb TJ
BMC Cancer; 2018 May; 18(1):556. PubMed ID: 29751789
[TBL] [Abstract][Full Text] [Related]
34. A fresh look at tumor immunosurveillance and immunotherapy.
Smyth MJ; Godfrey DI; Trapani JA
Nat Immunol; 2001 Apr; 2(4):293-9. PubMed ID: 11276199
[TBL] [Abstract][Full Text] [Related]
35. MHC class I antigens, immune surveillance, and tumor immune escape.
Garcia-Lora A; Algarra I; Garrido F
J Cell Physiol; 2003 Jun; 195(3):346-55. PubMed ID: 12704644
[TBL] [Abstract][Full Text] [Related]
36. Immunological responses can have both pro- and antitumour effects: implications for immunotherapy.
Stewart TJ; Greeneltch KM; Lutsiak ME; Abrams SI
Expert Rev Mol Med; 2007 Feb; 9(4):1-20. PubMed ID: 17284328
[TBL] [Abstract][Full Text] [Related]
37. [Immune response and cancer].
El Hage F; Abouzahr-Rifai S; Meslin F; Mami-Chouaib F; Chouaib S
Bull Cancer; 2008 Jan; 95(1):57-67. PubMed ID: 18230571
[TBL] [Abstract][Full Text] [Related]
38. Tumor escape from immune response: mechanisms and targets of activity.
Gabrilovich D; Pisarev V
Curr Drug Targets; 2003 Oct; 4(7):525-36. PubMed ID: 14535653
[TBL] [Abstract][Full Text] [Related]
39. Tumor escape from immune surveillance.
Costello RT; Gastaut JA; Olive D
Arch Immunol Ther Exp (Warsz); 1999; 47(2):83-8. PubMed ID: 10202560
[TBL] [Abstract][Full Text] [Related]
40. Mechanisms of tumor escape from immune system: role of mesenchymal stromal cells.
Poggi A; Musso A; Dapino I; Zocchi MR
Immunol Lett; 2014; 159(1-2):55-72. PubMed ID: 24657523
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
